

# Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028

<https://marketpublishers.com/r/G7F1EA18635DEN.html>

Date: April 2022

Pages: 240

Price: US\$ 3,000.00 (Single User License)

ID: G7F1EA18635DEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights:

Global Bcr-Abl Inhibitor Market Opportunity > USD 8 Billion

Approved Bcr-Abl Inhibitor Drugs: 8 Drugs

Global Bcr-Abl Inhibitor Market Regional Analysis & Forecast Till 2028

Bcr-Abl Inhibitor Drug Market Past Sales & Future Forecast Till 2028

Market Analysis By First, Second & Third Generation Approved drugs

Bcr-Abl Inhibitor Drug Prices, Dosage & Patent Insight

Global Bcr-Abl Inhibitor Drug clinical Trials Insight by Indication ,Company, County & Phase

Chronic myeloid leukemia is a myeloproliferative disorder which is characterized by the abnormal granulocyte cells proliferation. Since last two decades, there have been significant advances in the management of chronic myeloid leukemia. New drug class that has transformed the treatment of CML includes tyrosine kinases (TKIs) or BCR-ABL inhibitors. The BCR-ABL targets are downstream pathways including RAS,

PI3K/AKT, and JAK/STAT that address the transformation of healthy cells toward neoplastic cells responsible for pathogenesis of chronic myeloid leukemia, thus making it potential target for the drug development.

Imatinib was first Bcr-Abl inhibitor, which was approved by FDA in 2001 as first-line therapy for chronic myeloid leukemia. Unfortunately, the appearance of resistance phenomena required the development of a second generation of Bcr-Abl inhibitors. Currently three 2nd generation drugs including Nilotinib, Dasatinib and Bosulitinib whereas one 3rd generation drug, Ponatinib has been approved for the management of CML which have shown enhanced efficacy in comparison to already approved drugs. In addition, Olverembatinib which is third generation inhibitor developed by Ascentage Pharma has gained entry into China. The promising response of Bcr-Abl inhibitors in the market has propelled the further research and development activities in this domain.

Companies operating in the Bcr-Abl tyrosine kinase inhibitors industry are focusing on increasing their geographic presence by means of strategic acquisitions and collaborations with leading players and increasing FDA approvals of therapeutic drugs in their respective domains and geographies. For instance, Ascentage Pharma also announced a multifaced strategic collaboration with Innovent Biologics. This collaboration includes the joint clinical development and commercialization of Olverembatinib in China. Ascentage Pharma has recently announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted approval to Olverembatinib (HQP1351), for the treatment of patients with chronic phase CML resistant and/intolerant to first and second generation TKI.

US has been dominating the global Bcr-Abl inhibitor market driven by more than 100 clinical trials which are evaluating the role of novel Bcr-Abl inhibitors as monotherapy or combinational therapy in wide range of therapeutic indications. Further, the governments regulatory are also increasingly granting special designations such as orphan drug, breakthrough therapy, and others which promote the research and development. For instance in 2020, US FDA granted HQP1351 orphan drug designation for the treatment of patients with chronic myeloid leukemia. HQP1351 is a novel, orally active, potent third generation Bcr-Abl inhibitor which is designed to target Bcr-Abl mutants, including T3151.

As per our report findings, the global Bcr-Abl inhibitor market will surpass US\$ 8 Billion by 2028. The major factor attributing to the growth of the market is increasing prevalence of chronic myeloid leukemia (CML). Furthermore, growing investments in research and development programs by biotechnology and pharmaceutical companies

are also boosting the market growth. The development of favorable reimbursement policies and introduction of generics in the market will also drive the growth of market. The key companies in global Bcr-Abl inhibitor market are Ascentage Pharma, Incyte Pharmaceuticals, Novartis, Bristol Meyer Squibb, Ariad Pharmaceuticals, and others.

Our report provides in-depth analysis on the available Bcr-Abl inhibitors in the global market along with their commercial information. In addition, insights into ongoing clinical trials and key drugs in research and development are also included in the report. The report also provides profiles of leading players operating in the global tyrosine kinase inhibitors market. The report includes detailed analysis on market dynamics, market estimation and forecast for the period of 2022 to 2028. The report segments market on the basis of drug type and geographies.

## Contents

### **1. INTRODUCTION TO BCR-ABL INHIBITORS**

- 1.1 Overview
- 1.2 Evolution of Bcr-Abl Inhibitors

### **2. BCR-ABL INHIBITOR - MECHANISM OF ACTION**

- 2.1 Overview
- 2.2 Role of Bcr-Abl Inhibitor in Cancer

### **3. GLOBAL BCR-ABL INHIBITOR DRUG MARKET INSIGHT**

- 3.1 Current Market Scenario
- 3.2 Future Market Opportunity

### **4. BCR-ABL INHIBITOR DRUG MARKET REGIONAL ANALYSIS**

- 4.1 US
- 4.2 Europe
- 4.3 Japan
- 4.4 Rest of World

### **5. BCR-ABL INHIBITOR DRUG MARKET BY PRODUCT**

- 5.1 First Generation Bcr-Abl Inhibitor
- 5.2 Second Generation Bcr-Abl Inhibitor
- 5.3 Third Generation Bcr-Abl Inhibitor

### **6. IMATINIB – 1ST GENERATION BCR-ABL INHIBITOR 2001**

- 6.1 Overview
- 6.2 Patent & Exclusivity
- 6.3 Pricing & Dosage Analysis
  - 6.3.1 Branded
  - 6.3.2 Generic
- 6.4 Sales Analysis

## **7. DASATINIB – 2ND GENERATION BCR-ABL INHIBITOR 2006**

- 7.1 Overview
- 7.2 Patent & Exclusivity
- 7.3 Pricing & Dosage Analysis
  - 7.3.1 Branded
  - 7.3.2 Generic
- 7.4 Sales Analysis

## **8. NILOTINIB – 2ND GENERATION BCR-ABL INHIBITOR 2007**

- 8.1 Overview
- 8.2 Patent & Exclusivity
- 8.3 Price & Dosage Analysis
- 8.4 Sales Analysis

## **9. BOSUTINIB – 2ND GENERATION BCR-ABL INHIBITOR 2012**

- 9.1 Overview
- 9.2 Patent & Exclusivity
- 9.3 Pricing & Dosage Analysis
- 9.4 Sales Analysis

## **10. PONATINIB – 3RD GENERATION BCR-ABL INHIBITOR 2012**

- 10.1 Overview
- 10.2 Patent & Exclusivity
- 10.3 Pricing & Dosage Analysis
- 10.4 Sales Analysis

## **11. ASCIMINIB – 3RD GENERATION BCR-ABL INHIBITOR 2021**

- 11.1 Overview
- 11.2 Patent & Exclusivity
- 11.3 Pricing & Dosage Analysis

## **12. OLVEREMBATINIB – 3RD GENERATION BCR-ABL INHIBITOR 2021**

## **13. BCR-ABL INHIBITORS SALES FORECAST 2022 TILL 2028**

- 13.1 Gleevec/Glivec Sales Forecast
- 13.2 Sprycel Sales Forecast
- 13.3 Tasigna Sales Forecast
- 13.4 Bosulif Sales Forecast
- 13.5 Iclusig Sales Forecast

## **14. BCR-ABL INHIBITOR MARKET CLINICAL TRIAL INSIGHTS**

- 14.1 By Indication
- 14.2 By Organization
- 14.3 By Patient Segment
- 14.4 By Phase
- 14.5 By Status
- 14.6 By Region

## **15. GLOBAL BCR-ABL TYROSINE KINASE INHIBITORS CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE**

- 15.1 Preclinical
- 15.2 Clinical
- 15.3 Phase-I
- 15.4 Phase-I/II
- 15.5 Phase-II
- 15.6 Phase-II/III
- 15.7 Registered

## **16. MARKETED BCR-ABL INHIBITORS CLINICAL TRIALS INSIGHT**

## **17. BCR-ABL INHIBITORS MARKET DYNAMICS**

- 17.1 Market Favorable Parameters
- 17.2 Market Challenges

## **18. BCR-ABL INHIBITOR MARKET FUTURE PERSPECTIVE**

## **19. COMPETITIVE LANDSCAPE**

- 19.1 Ascentage Pharma

- 19.2 AstraZeneca
- 19.3 Bristol Myers Squibb
- 19.4 Fusion Pharmaceuticals
- 19.5 Incyte Pharmaceutical
- 19.6 Merck
- 19.7 Novartis
- 19.8 Pfizer
- 19.9 Takeda Pharmaceuticals
- 19.10 Teva Pharmaceutical

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Therapeutic Options for Management of CML
- Figure 1-2: Evolution of Bcr-Abl Inhibitors Development
- Figure 2-1: Imatinib – Mechanism of Action in CML
- Figure 2-2: Pathways Regulated by Bcr-Abl in Cancer
- Figure 3-1: Global – Leukemia Incidences & Death, 2020 & 2025
- Figure 3-2: Bcr-Abl Inhibitor - Drugs Sales (US\$ Million), 2021
- Figure 3-3: Bcr-Abl Inhibitor - Drugs Sales (US\$ Million), 2020
- Figure 3-4: Bcr-Abl Inhibitor - Drugs Sales (US\$ Million), 2019
- Figure 3-5: Bcr-Abl Inhibitor - Drugs Sales (US\$ Million), 2018
- Figure 3-6: Bcr-Abl Inhibitor - Drugs Market by Region (US\$ Billion), 2021
- Figure 3-7: Bcr-Abl Inhibitor - Drugs Market by Region (%), 2021
- Figure 3-8: Global – Bcr-Abl Inhibitors Drugs Market Size (US\$ Billion), 2022 - 2028
- Figure 4-1: US – Leukemia Incidences & Death, 2020 & 2025
- Figure 4-2: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (US\$ Billion), 2021
- Figure 4-3: US vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
- Figure 4-4: US – Bcr-Abl Inhibitors Drugs Market Size (US\$ Billion), 2022 - 2028
- Figure 4-5: Europe – Leukemia Incidences & Death, 2020 & 2025
- Figure 4-6: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (US\$ Billion), 2021
- Figure 4-7: Europe vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
- Figure 4-8: Europe – Bcr-Abl Inhibitors Drugs Market Size (US\$ Million), 2022 - 2028
- Figure 4-9: Japan – Leukemia Incidences & Death, 2020 & 2025
- Figure 4-10: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (US\$ Billion), 2021
- Figure 4-11: Japan vs. ROW - Bcr-Abl Inhibitor Drugs Market (%), 2021
- Figure 4-12: Japan – Bcr-Abl Inhibitors Drugs Market Size (US\$ Million), 2022 – 2028
- Figure 4-13: China – Leukemia Incidences & Death, 2020 & 2025
- Figure 4-14: India – Leukemia Incidences & Death, 2020 & 2025
- Figure 4-15: ROW – Bcr-Abl Inhibitors Drugs Market Size (US\$ Million), 2021 - 2028
- Figure 4-16: China – Bcr-Abl Inhibitors Drugs Market Size (US\$ Million), 2021 - 2028
- Figure 5-1: First Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
- Figure 5-2: First Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
- Figure 5-3: Global - First Generation Bcr-Abl Inhibitor Drugs Market Size (US\$ Million), 2022 - 2028
- Figure 5-4: Second Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
- Figure 5-5: Second Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021
- Figure 5-6: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (%), 2021



Figure 5-7: Second Generation Bcr-Abl Inhibitor Drugs Market by Drug Type (US\$ Million), 2021

Figure 5-8: Global - Second Generation Bcr-Abl Inhibitor Drugs Market Size (US\$ Million), 2022 - 2028

Figure 5-9: Third Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021

Figure 5-10: Third Generation vs. Others – Bcr-Abl Inhibitor Drugs Market (%), 2021

Figure 5-11: Global - Third Generation Bcr-Abl Inhibitor Drugs Market Size (US\$ Million), 2022 - 2028

Figure 6-1: US – Imatinib FDA Orphan Drug Designation by Indication

Figure 6-2: Imatinib – Approval Year by Region

Figure 6-3: US – Gleevec FDA Approval History by Indication

Figure 6-4: US – Gleevec Patent Approval & Expiration Year

Figure 6-5: Imatinib – 1st Generic Approval by Region

Figure 6-6: US – Cost of Supply of 90 Tablets & Per Unit Cost of Gleevec 100mg (US\$), March'2022

Figure 6-7: US – Cost of Supply of 30 Tablets & Per Unit Cost of Gleevec 400mg (US\$), March'2022

Figure 6-8: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Glivec 100mg (GBP/US\$), March'2022

Figure 6-9: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US\$), March'2022

Figure 6-10: US – Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 100mg (US\$), March'2022

Figure 6-11: US – Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 100mg (US\$), March'2022

Figure 6-12: US – Cost of Supply of 90 Tablets & Per Unit Cost of Imatinib 100mg (US\$), March'2022

Figure 6-13: US – Cost of Supply of 20 Tablets & Per Unit Cost of Imatinib 400mg (US\$), March'2022

Figure 6-14: US – Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 400mg (US\$), March'2022

Figure 6-15: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Imatinib 100mg (GBP/US\$), March'2022

Figure 6-16: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US\$), March'2022

Figure 6-17: Imatinib – Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)

Figure 6-18: Global - Gleevec/Glivec Annual Sales (US\$ Million), 2018-2021

Figure 6-19: Global - Gleevec/Glivec Quarterly Sales (US\$ Million), 2021

- Figure 6-20: Global - Gleevec/Glivec Quarterly Sales (US\$ Million), 2019 & 2020
- Figure 7-1: US - Sprycel Orphan Drug Designation Approval & Exclusivity for CML
- Figure 7-2: US - Sprycel Orphan Drug Designation Approval & Exclusivity for Ph+ ALL
- Figure 7-3: US - Sprycel Orphan Drug Designation & FDA Approval Year
- Figure 7-4: Sprycel – Approval Year by Region
- Figure 7-5: US – Sprycel Approval Year by Indication
- Figure 7-6: US – Sprycel Patent Approval & Expiration Year
- Figure 7-7: Japan – Sprycel Approval & Patent Exclusivity Year
- Figure 7-8: Europe – Branded & 1st Generic Approval Year
- Figure 7-9: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (US\$), March'2022
- Figure 7-10: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 50mg & 70mg (US\$), March'2022
- Figure 7-11: US – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 80mg, 100mg & 140mg (US\$), March'2022
- Figure 7-12: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US\$), March'2022
- Figure 7-13: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg & 140mg (GBP/US\$), March'2022
- Figure 7-14: UK – Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US\$), March'2022
- Figure 7-15: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg & 140mg (GBP/US\$), March'2022
- Figure 7-16: Dasatinib – Initial Recommended Dose by Indication for Adults (mg/day)
- Figure 7-17: Dasatinib – Initial Recommended Dose by Indication for Pediatric Patients by Weight (mg/day)
- Figure 7-18: Global - Sprycel Annual Sales (US\$ Million), 2017-2021
- Figure 7-19: US - Sprycel Annual Sales (US\$ Million), 2017-2021
- Figure 7-20: Sprycel – Annual Sales by Region (US\$ Million), 2021
- Figure 7-21: Sprycel – Annual Sales by Region (%), 2021
- Figure 7-22: Sprycel – Annual Sales by Region (%), 2020
- Figure 7-23: Global - Sprycel Quarterly Sales (US\$ Million), 2021
- Figure 7-24: US - Sprycel Quarterly Sales (US\$ Million), 2021
- Figure 7-25: Global - Sprycel Quarterly Sales (US\$ Million), 2020
- Figure 7-26: US - Sprycel Quarterly Sales (US\$ Million), 2020
- Figure 8-1: US - Tasigna Orphan Drug Designation Approval & Exclusivity for CML
- Figure 8-2: Tasigna – Approval Year by Region
- Figure 8-3: US - Tasigna Orphan Drug Designation & Approval Year
- Figure 8-4: Europe - Tasigna Orphan Drug Designation & Approval Year

- Figure 8-5: US – Tasigna Approval History by Indication
- Figure 8-6: US – Tasigna Patent Approval & Expiration Year
- Figure 8-7: Canada – Tasigna Patent Approval & Expiration Year
- Figure 8-8: US – Tasigna FDA Approval & Patent Exclusivity Year
- Figure 8-9: Europe – Tasigna EMA Approval & Patent Exclusivity Year
- Figure 8-10: US – Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (US\$), March'2022
- Figure 8-11: US – Cost of Supply of 28 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (US\$), March'2022
- Figure 8-12: US – Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (US\$), March'2022
- Figure 8-13: UK – Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (GBP/US\$), March'2022
- Figure 8-14: UK – Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (GBP/US\$), March'2022
- Figure 8-15: Nilotinib – Initial Recommended Dose by Indication (mg/day)
- Figure 8-16: Nilotinib – Minimum & Maximum Recommended Dose in Pediatric CML (mg/day)
- Figure 8-17: Global - Tasigna Annual Sales (US\$ Million), 2018-2021
- Figure 8-18: Global - Tasigna Quarterly Sales (US\$ Million), 2021
- Figure 8-19: Global - Tasigna Quarterly Sales (US\$ Million), 2019 & 2020
- Figure 9-1: US - Bosulif Orphan Drug Designation Approval & Exclusivity for CML
- Figure 9-2: Bosulif – Approval Year by Region
- Figure 9-3: US - Bosulif Orphan Drug Designation & Approval Year
- Figure 9-4: US - Bosulif Approval by Indication
- Figure 9-5: US – Bosulif Patent Approval & Expiration Year
- Figure 9-6: Europe – Bosutif EMA Approval & Patent Exclusivity Year
- Figure 9-7: US – Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 100mg (US\$), March'2022
- Figure 9-8: US – Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 400mg & 500mg (US\$), March'2022
- Figure 9-9: UK – Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 100mg (GBP/US\$), March'2022
- Figure 9-10: UK – Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 400mg & 500mg (GBP/US\$), March'2022
- Figure 9-11: Bosutinib – Initial Recommended Dose by Indication for Adults (mg/day)
- Figure 9-12: Bosutinib – Minimum & Maximum Recommended Dose (mg/day)
- Figure 9-13: Global - Bosulif Annual Sales (US\$ Million), 2017-2021
- Figure 9-14: US - Bosulif Annual Sales (US\$ Million), 2017-2021

- Figure 9-15: Europe - Bosulif Annual Sales (US\$ Million), 2017-2021
- Figure 9-16: Bosulif – Annual Sales by Region (US\$ Million), 2021
- Figure 9-17: Bosulif – Annual Sales by Region (%), 2021
- Figure 9-18: Bosulif – Annual Sales by Region (%), 2020
- Figure 9-19: Global - Bolusif Quarterly Sales (US\$ Million), 2021
- Figure 9-20: US - Bolusif Quarterly Sales (US\$ Million), 2021
- Figure 9-21: Europe - Bolusif Quarterly Sales (US\$ Million), 2021
- Figure 9-22: Global - Bosulif Quarterly Sales (US\$ Million), 2020
- Figure 9-23: US - Bosulif Quarterly Sales (US\$ Million), 2020
- Figure 10-1: Iclusig - Orphan Drug Designation by Region
- Figure 10-2: US - Iclusig Orphan Drug Designation & Approval Year
- Figure 10-3: Europe - Iclusig Orphan Drug Designation & Approval Year
- Figure 10-4: Iclusig – Approval Year by Region
- Figure 10-5: US – Iclusig Approval by Indication
- Figure 10-6: US – Iclusig Patent Approval & Expiration Year
- Figure 10-7: Europe – Iclusig EMA Approval & Patent Exclusivity Year
- Figure 10-8: Japan – Iclusig Approval & Patent Exclusivity Year
- Figure 10-9: US – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig Oral Tablet (US\$), March'2022
- Figure 10-10: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 15mg (GBP/US\$), March'2022
- Figure 10-11: UK – Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 30mg & 45mg (GBP/US\$), March'2022
- Figure 10-12: Ponatinib – Initial & Dose Reductions for CP-CML (mg/day)
- Figure 10-13: Ponatinib – Initial & Dose Reductions for Resistant CML & Ph+ ALL (mg/day)
- Figure 10-14: Global - Inlusig Annual Sales (US\$ Million), 2017-2021
- Figure 10-15: Global - Inlusig Quarterly Sales (US\$ Million), 2021
- Figure 10-16: Global - Inlusig Quarterly Sales (US\$ Million), 2019 & 2020
- Figure 11-1: US - Scemblix Orphan Drug Designation & Approval Year
- Figure 11-2: US – Scemblix Patent Issue & Expiration Year
- Figure 11-3: US – Scemblix FDA Approval & Patent Exclusivity Year
- Figure 11-4: US – Cost of Supply of 60 Tablets & Per Unit Cost of Scemblix Oral Tablet (US\$), March'2022
- Figure 11-5: Scemblix – Initial & Dose Reductions for Ph+ CML-CP, Previously Treated with Two or More TKIs (mg/day)
- Figure 11-6: Scemblix – Initial & Dose Reductions for Ph+ CML-CP with the T315I Mutation (mg/day)
- Figure 12-1: China – Olverembatinib Priority Review, Breakthrough Therapy

Designation & NMPA Approval Year

Figure 12-2: Olverembatinib – Orphan Designation by Region

Figure 13-1: Global - Glivec/Gleevec Sales Forecast (US\$ Million), 2022 - 2028

Figure 13-2: Global - Sprycel Sales Forecast (US\$ Million), 2022 - 2028

Figure 13-3: US - Sprycel Sales Forecast (US\$ Million), 2022 - 2028

Figure 13-4: ROW - Sprycel Sales Forecast (US\$ Million), 2022 - 2028

Figure 13-5: Global - Tasigna Sales Forecast (US\$ Million), 2022 - 2028

Figure 13-6: Global – Bolusif Sales Forecast (US\$ Million), 2022 – 2028

Figure 13-7: US – Bolusif Sales Forecast (US\$ Million), 2022 – 2028

Figure 13-8: Europe – Bolusif Sales Forecast (US\$ Million), 2022 – 2028

Figure 13-9: ROW – Bolusif Sales Forecast (US\$ Million), 2022 – 2028

Figure 13-10: Global – Iclusig Sales Forecast (US\$ Million), 2022 - 2028

Figure 14-1: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Indication, April'2022

Figure 14-2: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by organization, April'2022

Figure 14-3: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Patient Segment, April'2022

Figure 14-4: BCR-ABL Inhibitor - Number of Drugs in Clinical Trials by Phase, April'2022

Figure 14-5: BCR-ABL Inhibitor - Number of Clinical Trials by Status, March'2022

Figure 14-6: BCR-ABL Inhibitor - Number of Clinical Trials by Region, March'2022

Figure 14-7: North America – Bcr-Abl Inhibitors Number of Clinical Trial by Countries, March'2022

Figure 17-1: Bcr-Abl Inhibitor Market – Favorable Parameters

Figure 17-2: BCR-ABL Inhibitor Market Challenges

## I would like to order

Product name: Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/G7F1EA18635DEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7F1EA18635DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970